Pregabalin Capsule
Product Images NDC 71335-1555

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71335-1555). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713351555)

This is a product description for Pregabalin Capsules, with each capsule containing 200mg of the medication. The NDC number and storage instructions are provided, with a caution to keep the drug away from children. The recommended storage temperature range is given, along with instructions for excursions. This medicine is available only by prescription, and a standard package contains 30 capsules.*

FDA Label Image

Label (Lbl7133515552)

This is a label for a medication package that contains a drug named "Bryant Ranck Prepack". It suggests to compare it with a drug named "Lyrica 200mg (CV) Capsule" made by "Laurus Labs Limited". It also mentions an expiration date with the format MM/YY and a NDC code. It is recommended to store the medication at room temperature and keep it away from children.*

FDA Label Image

Pregabalinchemistrystructure (Pregabalin Chem Structure)

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

FDA Label Image

Pregabalinfig1 (Pregabalin Fig 01)

Percent of Patients Improved: This text provides information on the percentage of patients who have improved. However, the manner in which it is presented is not entirely clear, as there are some numbers and characters that are difficult to interpret.*

FDA Label Image

Pregabalinfig2 (Pregabalin Fig 02)

The text describes a chart or table showing the percentage improvement in pain for patients. It looks like there are different values for different treatments or medications, including Pregabalin 160 mg. However, the chart or table is incomplete and some of the text is not clear, including the meaning of the values in the bottom row.*

FDA Label Image

Pregabalinfig3 (Pregabalin Fig 03)

This text appears to be a combination of numbers, medication names, and a chart showing percentages. It is not possible to generate a useful description without additional context. The text may be related to a study or analysis of patient outcomes and pain management.*

FDA Label Image

Pregabalinfig4 (Pregabalin Fig 04)

Not available.*

FDA Label Image

Pregabalinfig5 (Pregabalin Fig 05)

This appears to be a table displaying the number of patients who improved after taking either Fregabalin 100mg three times a day, Pregabalin 80mg three times a day, or a placebo. The following row shows the percentage of patients who saw improvement in pain from their baseline.*

FDA Label Image

Pregabalinfig6 (Pregabalin Fig 06)

FDA Label Image

Pregabalinfig7 (Pregabalin Fig 07)

FDA Label Image

Pregabalinfig8 (Pregabalin Fig 08)

This seems to be a chart or a table showing different doses of pregabalin, a medication used to treat neuropathic pain, and a placebo, and their effectiveness in improving pain compared to the baseline. However, the text is not completely readable, and therefore, the information is not clear.*

FDA Label Image

Pregabalinfig9 (Pregabalin Fig 09)

FDA Label Image

Pregabalinfig10 (Pregabalin Fig 10)

Not-Available. The text appears to be a chart or table with numerical values, but without context or column headers, it is impossible to determine what the data represents.*

FDA Label Image

Pregabalinfig11 (Pregabalin Fig 11)

The table indicates the percentage of subjects improved after a certain duration of treatment, specifically 16 weeks, using Pregabalin and Placebo. The improvement scale is plotted against various values ranging from 100 to 280.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.